The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem
The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting.
대표청구항▼
1. A population of isolated adherent placental stem cells, wherein said stem cells: express genes at a detectably higher level than an equivalent number of bone marrow-derived mesenchymal stem cells (BM-MSCs); wherein said genes comprise ELOVL2, ST3GAL6, ST6GALNAC5, or SLC12A8; wherein at least 70%
1. A population of isolated adherent placental stem cells, wherein said stem cells: express genes at a detectably higher level than an equivalent number of bone marrow-derived mesenchymal stem cells (BM-MSCs); wherein said genes comprise ELOVL2, ST3GAL6, ST6GALNAC5, or SLC12A8; wherein at least 70% of said placental stem cells are non-maternal in origin; andwherein said cells have been passaged at least three times and cultured under growth conditions. 2. The population of claim 1, wherein at least 90% of said placental stem cells are non-maternal in origin. 3. The population of claim 1 present in a form suitable for intravenous administration. 4. The population of claim 1, wherein said cells have the capacity to differentiate into cells having characteristics of neural cells. 5. The population of claim 1, wherein said genes further comprise CD200 and NUAK1. 6. The population of claim 1, wherein said genes further comprise ARTS-1, IER3, IL6, KRT18, LRAP, MEST, NFE2L3, or TGFB2. 7. The population of claim 1, wherein said expression of said genes is detectably higher level than an equivalent number of bone marrow-derived mesenchymal stem cells over 3 population doublings. 8. The population of claim 1, wherein said expression of said genes is detectably higher level than an equivalent number of bone marrow-derived mesenchymal stem cells over 11-14 population doublings. 9. The population of claim 1, wherein said expression of said genes is detectably higher level than an equivalent number of bone marrow-derived mesenchymal stem cells over 24-38 population doublings. 10. The population of claim 1, wherein said population comprises at least 1 ×109 cells. 11. The population of claim 1, wherein said population has undergone at least 5 population doublings. 12. The population of claim 1, additionally comprising stem cells that are not obtained from placental tissue. 13. The population of claim 12, wherein said stem cell not obtained from a placenta is a mesenchymal stem cell. 14. The population of claim 12, wherein said stem cells not obtained from a placenta are hematopoietic progenitor cells. 15. The population of claim 1, wherein said cells have been cryopreserved. 16. The population of claim 1, wherein said cells express said one or more genes at a detectably higher level than an equivalent number of BM-MSCs in medium comprising DMEM-LG and MCDB-201; 2% fetal calf serum, 1× insulin-transferrin-selenium, 1× lenolenic-acid-bovine-serum-albumin, 10−9 M dexamethasone, 10−4 M ascorbic acid 2-phosphate, 10 ng/ml epidermal growth factor, and 10 ng/ml platelet derived-growth factor. 17. The population of claim 1, wherein said placental cells have the ability to replicate 10-40 times in culture. 18. The population of claim 1, wherein said placental cells have the ability to replicate 10-40 times in culture in DMEM and fetal bovine serum. 19. The population of claim 1, wherein said placental cells are isolated from a human postpartum placenta by digestion using trypsin, or are cultured from cells isolated from a human postpartum placenta by digestion using trypsin. 20. The population of clam 1, wherein said placental cells have been separated from at least 90% of cells from the placenta from which the placental cells are isolated. 21. The population of claim 1, wherein said population comprises 1×108 to 5×108 placental stem cells. 22. The population of claim 1, wherein said population comprises 5×108 to 1×109 placental stem cells. 23. The population of claim 1, wherein said population comprises 1×109 to 5×109 placental stem cells. 24. The population of claim 1, wherein said placental stem cells have been passaged 4 to 8 times. 25. The population of claim 1, wherein said placental stem cells have been passaged 6 times. 26. The population of claim 1, wherein said placental cells have undergone 18 to 26 population doublings. 27. The population of claim 1, wherein said placental stem cells have a doubling time of three to five days. 28. The population of claim 1, wherein said population is present in a composition comprising dimethylsulfoxide (DMSO), human serum albumin (HSA), or dextran. 29. The population of claim 1, wherein said placental stem cells differentiate into cells having a characteristic of chondrogenic cells when cultured in DMEM comprising 15% cord blood serum and 0.01 μg/mL transforming growth factor beta (TGFβ); and wherein said characteristic of chondrogenic cells is positive staining with Alcian Blue stain. 30. The population of claim 1, wherein said placental stem cells differentiate into cells having a characteristic of osteogenic cells when cultured in DMEM comprising 15% cord blood serum, 0.1 μM dexamethasone, 0.05 mM ascorbic acid-2-phosphate, and 10 mM beta glycerophosphate; and wherein said characteristic of osteogenic cells is staining with von Kossa stain or production of mRNA for alkaline phosphatase as determined by RT-PCR. 31. The population of claim 1, wherein at least 90% of cells in the population are said placental stem cells. 32. The population of claim 1, wherein at least 95% of cells in the population are said placental stem cells. 33. The population of claim 1, wherein at least 99% of cells in the population are said placental stem cells. 34. The population of claim 1, wherein said cells express said genes at least at a three-fold higher level than an equivalent number of BM-MSCs. 35. The population of claim 1, wherein said genes comprise ELOVL2. 36. The population of claim 1, wherein said genes comprise ST3GAL6. 37. The population of claim 1, wherein said genes comprise ST6GALNAC5. 38. The population of claim 1, wherein said genes comprise SLC12A8.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (163)
Pittenger Mark F., Adipogenic differentiation of human mesenchymal stem cells.
Kuypers Franciscus A. ; Cole Robert B. ; Meyst Richard P. ; Gorton Lanny A. ; Wright James I., Apparatus and method for collecting blood from an umbilical cord.
Kuypers Franciscus A. ; Cole Robert B. ; Meyst Richard P. ; Gorton Lanny A. ; Wright James I., Apparatus and method for collecting blood from an umbilical cord.
Kuypers Franciscus A. ; Cole Robert B. ; Meyst Richard P. ; Gorton Lanny A. ; Wright James I., Apparatus and method for collecting blood from an umbilical cord.
Capecchi Mario R. (Salt Lake City UT) Thomas Kirk R. (Salt Lake City UT), Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and.
Capecchi Mario R. (Salt Lake City UT) Thomas Kirk R. (Salt Lake City UT), Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and.
Heidaran, Mohammad; Wang, Jia-Lun; Ye, Qian; Zeitlin, Andrew; Dulaney, Colleen Suzanne, Co-culture of placental stem cells and stem cells from a second source.
Emerson Stephen G. (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Palsson Bernhard O. (Ann Arbor MI), Compositions containing cultured mitotic human stem cells.
Caplan Arnold I. ; Haynesworth Stephen E. ; Gerson Stanton L. ; Lazarus Hillard M., Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells.
Bauer S. Christopher ; Abrams Mark Allen ; Braford-Goldberg Sarah Ruth ; Caparon Maire Helena ; Easton Alan Michael ; Klein Barbara Kure ; McKearn John Patrick ; Olins Peter O. ; Paik Kumnan ; Thomas, Ex-vivo expansion of stem cells using combinations of interleukin-3 (IL-3) variants and other cytokines.
Bjornson Christopher R. ; Rietze Rod L.,AUX ; Reynolds Brent A.,CAX ; Vescovi Angelo L.,ITX, Generation of hematopoietic cells from multipotent neural stem cells.
Nakahata Tatsutoshi (Matsumoto JPX) Kawano Genji (Kamakura JPX) Sudo Tetsuo (Kamakura JPX) Kojima Katsuaki (Yokohama JPX), Hematopoietic stem cell growth-promoting compositions containing a fibroblast-derived fragment of fibronectin and a grow.
Rubinstein Pablo ; Coelho Philip Henry ; Stevens Cladd E., High concentration white cells, a method for agglomeration of the high concentration and a bag set for use in conjuncti.
Janice M. Davis-Sproul ; Mark Aaron Moorman ; Renee Marie McNeil ; Donald William Simonetti, Jr. ; Lora Catherine Hammill ; Stewart Craig, Human mesenchymal stem cells.
Srour Edward (Indianapolis IN) Zanjani Esmail (Reno NV) Brandt John E. (Indianapolis IN) Hoffman Ronald (Indianapolis IN), Human stem cell compositions and methods.
Tsukamoto Ann (Palo Alto CA) Baum Charles M. (Mountain View CA) Aihara Yukoh (Yokohama JPX) Weissman Irving (Palo Alto CA), Identification and isolation of human hematopoietic stem cells.
Johnson R. Paul (Lexington MA) Rosenzweig Michael (Boston MA) Scadden David T. (Weston MA), In vitro differentiation of CD34+progenitor cells into T lymphocytes.
Prockop Darwin J. ; Pereira Ruth F. ; Leeper Dennis B. ; O'Hara Michael D., Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects.
Edward A. Boyse ; Hal E. Broxmeyer ; Gordon W. Douglas, Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood.
Boyse Edward A. (Tucson AZ) Broxmeyer Hal E. (Indianapolis IN) Douglas Gordon W. (New York NY), Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of the.
Pykett, Mark J.; Rosenzweig, Michael; Scadden, David T.; Poznansky, Mark C., Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices.
Kevin R. McIntosh ; Joseph D. Mosca ; Elena N. Klyushnenkova, Mesenchymal stem cells for prevention and treatment of immune responses in transplantation.
McIntosh Kevin R. ; Mosca Joseph D. ; Klyushnenkova Elena N., Mesenchymal stem cells for prevention and treatment of immune responses in transplantation.
McIntosh, Kevin R.; Mosca, Joseph D.; Klyushnenkova, Elena, Mesenchymal stem cells for prevention and treatment of immune responses in transplantation.
Caplan Arnold I. (1300 Oakridge Dr. Cleveland Heights OH 44121) Haynesworth Stephen E. (3643 Antisdale Rd. Cleveland Heights OH 44118), Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells.
Emerson Stephen G. (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Palsson Bernhard O. (Ann Arbor MI), Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultur.
Caplan Arnold I. (1300 Oakridge Dr. Cleveland Heights OH 44121) Haynesworth Stephen E. (3643 Antisdale Rd. Cleveland Heights OH 44118), Method for treating connective tissue disorders.
Murray Lesley (San Jose CA) Sutherland D. Robert (Oakville CAX), Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby an.
Emerson Stephen G. (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Palsson Bernhard O. (Ann Arbor MI) Schwartz Richard M. (Ann Arbor MI), Methods and compositions for the ex vivo replication of human hematopoietic stem cells.
Emerson Stephen G. ; Clarke Michael F. ; Palsson Bernhard O., Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 sec.
Anderson David J. ; Shah Nirao M., Methods for differentiating neural stem cells to neurons or smooth muscle cells using TGT-.beta. super family growth factors.
Csete Marie ; Doyle John ; Wold Barbara, Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells.
Palsson Bernhard O. (Ann Arbor MI) Armstrong R. Douglas (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Emerson Stephen G. (Ann Arbor MI), Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture.
Emerson Stephen G. (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Palsson Bernhard O. (Ann Arbor MI), Methods for the ex vivo replication of human stem cells and/or expansion of human progenitor cells.
Hill Beth Louise ; Rozler Elen ; Chen Benjamin P., Methods of obtaining compositions enriched for hematopoietic stem cells, antibodies for use therein, compositions derived therefrom and methods of use thereof.
Emerson Stephen G. (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Palsson Bernhard O. (Ann Arbor MI), Methods, compositions and devices for growing human hematopoietic cells.
Palsson Bernhard O. ; Emerson Stephen G. ; Schwartz Richard M., Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells.
Hariri,Robert J.; Stirling,David I.; Moutouh De Parseval,Laure A.; Chan,Kyle W. H., Modulation of stem and progenitor cell differentiation, assays, and uses thereof.
Vyakarnam Murty N. ; Zimmerman Mark C. ; Scopelianos Angelo George ; Roller Mark B. ; Gorky David V., Porous tissue scaffoldings for the repair of regeneration of tissue.
Vyakarnam, Murty N.; Zimmerman, Mark C.; Scopelianos, Angelo George; Roller, Mark B.; Gorky, David V., Porous tissue scaffoldings for the repair or regeneration of tissue.
Boyse Edward A. (New York NY) Broxmeyer Hal E. (Indianapolis IN) Douglas Gordon W. (New York NY), Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood.
McIntosh, Kevin; Klyushnenkova, Elena, Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation.
Gerson Stanton L. (Pepper Pike OH) Caplan Arnold I. (Cleveland Heights OH) Haynesworth Stephen E. (Cleveland Heights OH), Transduced mesenchymal stem cells.
Hessel Stephen R. (Fountain Valley CA) Young H. Theodore (Lake Forest CA) Katz Michael (Richmond CA), Umbilical cord clamping, cutting, and blood collecting device and method.
Abramson, Sascha D.; Guelakis, Marian; Heidaran, Mohammad A.; Labazzo, Kristen; Yaccoby, Shmuel, Methods and compositions for treatment of bone defects with placental cell populations.
Edinger, James W.; Hariri, Robert J.; Wang, Jia-Lun; Ye, Qian; Labazzo, Kristen S.; Pereira, Marian; Abramson, Sascha Dawn, Methods and compositions for treatment of bone defects with placental cell populations.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.